Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
NAMS Stock Chart & Stats
$31.57
-$0.03(-0.12%)
At close: 4:00 PM EST
$31.57
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$14.06 - $42.00
Previous CloseN/A
Volume118.30K
Average Volume (3M)605.04K
Market Cap
$3.53B
Enterprise Value$3.04B
Total Cash (Recent Filing)$702.95M
Total Debt (Recent Filing)$266.00K
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 04, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding113,390,800
10 Day Avg. Volume469,170
30 Day Avg. Volume605,042
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)3.20
Price to Sales (P/S)53.22
P/FCF Ratio-15.23
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue86.30
Enterprise Value/Gross Profit86.30
Enterprise Value/Ebitda-10.56
Forecast
1Y Price Target
$49.00Price Target Upside55.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$45.04M
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesAnalyst notes blinded event rates in PREVAIL are tracking similarly to prior studies including BROADWAY, suggesting the trial may confirm meaningful reductions in major cardiovascular events.
Product DifferentiationAnalyst emphasizes obicetrapib's once‑daily oral dosing, substantial LDL‑C and Lp(a) reductions, and placebo‑like tolerability as features that could drive wide adoption versus injectable alternatives.
Regulatory ProgressAnalyst highlights EMA acceptance of marketing applications for obicetrapib and a fixed‑dose combination, setting up the potential for European approval and a commercial launch in 2026.
Bears Say
Catalyst Concentration RiskContinued uncertainty over PREVAIL event timing concentrates program risk on a single pivotal readout, which could magnify downside if outcomes or timing disappoint investor expectations.
Readout Timing UncertaintyManagement's planned update on PREVAIL timing amid uncertainty about event accrual creates ambiguity around when pivotal results will be available, increasing the risk of prolonged stock volatility.
Visibility And Planning RiskLimited visibility into PREVAIL event accrual complicates investor forecasting and commercial planning, potentially delaying decisions by partners and payors if clarity is not provided.
NewAmsterdam Pharma Company News
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $42.00 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $3.53B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Mar 04, 2026 which is in 28 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Nov 05, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.219.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.39.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 113,390,800 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 4.353%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (55.21% Upside)
$49.00 (55.21% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 990.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.63%
12-Months-Change
Fundamentals
Return on Equity
-39.94%
Trailing 12-Months
Asset Growth
79.06%
Trailing 12-Months
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$49.00
▲(55.21% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Soleno Therapeutics
―
Kiniksa Pharmaceuticals
―
Immunovant
―
Ownership Overview
Currently, No data available
---